Calcitonin Gene–Related Peptide–Exposed Endothelial Cells Bias Antigen Presentation to CD4+ T Cells toward a Th17 Response
Calcitonin gene–related peptide (CGRP) is a neuropeptide with well-established immunomodulatory functions. CGRP-containing nerves innervate dermal blood vessels and lymph nodes. We examined whether CGRP regulates the outcome of Ag presentation by Langerhans cells (LCs) to T cells through actions on microvascular endothelial cells (ECs). Exposure of primary murine dermal microvascular ECs (pDMECs) to CGRP followed by coculture with LCs, responsive CD4+ T cells and Ag resulted in increased production of IL-6 and IL-17A accompanied by inhibition of IFN-γ, IL-4, and IL-22 compared with wells containing pDMECs treated with medium alone. Physical contact between ECs and LCs or T cells was not required for this effect and, except for IL-4, we demonstrated that IL-6 production by CGRP-treated pDMECs was involved in these effects. CD4+ cells expressing cytoplasmic IL-17A were increased, whereas cells expressing cytoplasmic IFN-γ or IL-4 were decreased by the presence of CGRP-treated pDMECs. In addition, the level of retinoic acid receptor–related orphan receptor γt mRNA was significantly increased, whereas T-bet and GATA3 expression was inhibited. Immunization at the site of intradermally administered CGRP led to a similar bias in CD4+ T cells from draining lymph node cells toward IL-17A and away from IFN-γ. Actions of nerve-derived CGRP on ECs may have important regulatory effects on the outcome of Ag presentation with consequences for the expression of inflammatory skin disorders involving Th17 cells.
Top-30
Journals
|
1
2
|
|
|
Journal of Immunology
2 publications, 5.41%
|
|
|
Frontiers in Immunology
2 publications, 5.41%
|
|
|
Brain Behavior & Immunity - Health
2 publications, 5.41%
|
|
|
Immunology
2 publications, 5.41%
|
|
|
Acta Physiologica
2 publications, 5.41%
|
|
|
International Journal of Molecular Sciences
2 publications, 5.41%
|
|
|
Medecine/Sciences
1 publication, 2.7%
|
|
|
Dermatology
1 publication, 2.7%
|
|
|
Medicina
1 publication, 2.7%
|
|
|
Zeitschrift fur Rheumatologie
1 publication, 2.7%
|
|
|
Nature Reviews Neuroscience
1 publication, 2.7%
|
|
|
Cellular and Molecular Life Sciences
1 publication, 2.7%
|
|
|
Nature Reviews Immunology
1 publication, 2.7%
|
|
|
Allergy, Asthma and Clinical Immunology
1 publication, 2.7%
|
|
|
Current Treatment Options in Allergy
1 publication, 2.7%
|
|
|
Journal of Neuroimmunology
1 publication, 2.7%
|
|
|
Environmental Pollution
1 publication, 2.7%
|
|
|
Neuropeptides
1 publication, 2.7%
|
|
|
International Immunopharmacology
1 publication, 2.7%
|
|
|
Trends in Immunology
1 publication, 2.7%
|
|
|
Brain, Behavior, and Immunity
1 publication, 2.7%
|
|
|
BioMed Research International
1 publication, 2.7%
|
|
|
Trends in Neurosciences
1 publication, 2.7%
|
|
|
Journal of Allergy and Clinical Immunology
1 publication, 2.7%
|
|
|
Frontiers in Neurology
1 publication, 2.7%
|
|
|
Cell Reports
1 publication, 2.7%
|
|
|
Annals of Plastic Surgery
1 publication, 2.7%
|
|
|
Cellular Signalling
1 publication, 2.7%
|
|
|
Biomedicines
1 publication, 2.7%
|
|
|
1
2
|
Publishers
|
2
4
6
8
10
12
14
|
|
|
Elsevier
13 publications, 35.14%
|
|
|
Springer Nature
6 publications, 16.22%
|
|
|
MDPI
4 publications, 10.81%
|
|
|
Wiley
4 publications, 10.81%
|
|
|
Frontiers Media S.A.
3 publications, 8.11%
|
|
|
The American Association of Immunologists
2 publications, 5.41%
|
|
|
Editions E D K
1 publication, 2.7%
|
|
|
S. Karger AG
1 publication, 2.7%
|
|
|
Hindawi Limited
1 publication, 2.7%
|
|
|
Federal Medical Biological Agency
1 publication, 2.7%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 2.7%
|
|
|
2
4
6
8
10
12
14
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.